Western Standard LLC Acquires Shares of 285,931 2seventy bio, Inc. (NASDAQ:TSVT)

Western Standard LLC acquired a new position in shares of 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 285,931 shares of the company's stock, valued at approximately $1,350,000. 2seventy bio comprises about 1.3% of Western Standard LLC's portfolio, making the stock its 21st biggest holding. Western Standard LLC owned about 0.55% of 2seventy bio as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. State Street Corp grew its holdings in shares of 2seventy bio by 1.5% in the 3rd quarter. State Street Corp now owns 1,058,773 shares of the company's stock valued at $4,997,000 after buying an additional 15,638 shares during the period. Marshall Wace LLP lifted its holdings in 2seventy bio by 50.4% during the second quarter. Marshall Wace LLP now owns 667,023 shares of the company's stock worth $2,568,000 after acquiring an additional 223,408 shares in the last quarter. Venator Management LLC grew its stake in 2seventy bio by 49.2% in the second quarter. Venator Management LLC now owns 485,000 shares of the company's stock valued at $1,867,000 after acquiring an additional 160,000 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of 2seventy bio by 5.4% in the second quarter. Bank of New York Mellon Corp now owns 196,959 shares of the company's stock worth $758,000 after acquiring an additional 10,077 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC raised its position in shares of 2seventy bio by 39.1% during the second quarter. Susquehanna Fundamental Investments LLC now owns 192,319 shares of the company's stock worth $740,000 after purchasing an additional 54,076 shares during the period. Institutional investors and hedge funds own 93.90% of the company's stock.

2seventy bio Price Performance

Shares of 2seventy bio stock traded up $0.13 on Friday, hitting $3.54. The company had a trading volume of 106,102 shares, compared to its average volume of 730,793. The stock has a 50-day moving average of $4.42 and a 200-day moving average of $4.39. 2seventy bio, Inc. has a twelve month low of $2.29 and a twelve month high of $6.40. The firm has a market capitalization of $182.62 million, a P/E ratio of -1.95 and a beta of 1.69.

2seventy bio Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.